Recently, Malaysia Pandora Bio Technology and Shenzhen KK Medical Research Institute held a biomedical technology (industry) development strategic cooperation signing ceremony, and the "radar + GPS" type KK-Umh-NK01V technology transformation research and application ceremony, this time The signing of the cooperation also indicates that the two companies will further cooperate in the field of biomedicine, and focus on researching the sequelae of patients infected with new coronary pneumonia, aiming to reduce the possibility of sequelae of patients. Improve their own medical technology from cooperation, and use the advantages of the two companies to jointly build a sense of community with a shared future for mankind.
Data source:
Baidu Global COVID-19 Big Data Analysis Platform
According to statistics, as of April 12, 2022, there have been 499,748,065 confirmed cases of new coronary pneumonia worldwide, and a total of 6,181,560 deaths. This data also reflects the spread of new coronary pneumonia. Although the current prevention and control measures have been very strict, and research and analysis of diseased strains have continued, the new coronavirus is still constantly mutating. It also makes people pay more attention to their own immunity. It is also gradually understood that the primary condition for prevention and control is to rely on the human immune system. However, due to the rapid mutation rate of the virus, after the new mutated virus enters the human body, the autonomous immune system cannot quickly recognize and send a signal to kill the virus, which leads to the human body being infected with the virus. Therefore, the use of injection vaccine is to stimulate the body. Immune formation is one of the measures to identify and kill new viruses. Modern biomedical research has found that it is also an effective measure to achieve anti-virus and kill new coronaviruses through "spot NK cell injection" back into the body. At present, the FDA has approved the spot-type CYNK-001 and K-NK-001 technologies respectively for the treatment of new coronary pneumonia, the prevention of high-risk groups and the preemptive treatment after exposure. The safety and effectiveness of their technologies have been recognized by the industry.
Image source:
Relevant literature (reference) states that the technical logic diagram described in this report
is confidential information and will not be released for the time being.
It is understood that while Malaysia Pandora Bio Technology and Shenzhen KK Medical Research Institute are committed to basic research, they will also use their own technological and capital advantages to focus on research and development in frontier and source research fields, and strengthen breakthroughs in core key technologies , explore the realization of basic research and industrial technology innovation and development, and invest a lot of manpower and material resources. Based on the previous research results of Shenzhen KK Medical Research Institute, a "spot type" has been completed at a very efficient speed and can be completed within 96 hours. Transport and carry "radar + GPS" type Umh-NK01V technology application at room temperature, this technology can achieve emergency identification and killing of new crown and other epidemic infectious viruses, and can immediately start cracking, killing virus and clearing the virus after directional identification of the virus. The perforin, granzyme, lysosome and IFN-r of the host cells invaded by virus particles form a powerful ADCC killing effect, which can effectively lyse and clear the invading virus, and relieve or even cure the pulmonary inflammation caused by virus infection and other factors. The sequelae of the new crown caused by the virus. After the new coronavirus invades the human body, its surface SpiKe protein enters the nucleus by recognizing the ACE2 protein of the human host, causing the host cell to evolve into a thrombotic substance, resulting in a state of double the risk of cardiovascular and cerebrovascular diseases. After the implementation of this technology, it is expected to achieve active recognition. And lyse host cells with Spike protein, and reduce the risk of cardiovascular and cerebrovascular diseases. While the research initiated by the R&D team has achieved good expected results, the research also found that this technology can effectively activate the body's ability to recognize viruses, improve immunity, reduce the risk of reinfection, and strengthen and shape the immune barrier for the body to defend against virus invasion.
Description:
Spot type KK-Umh-NK-001 preparation storage and application process
(refer to the schematic diagram)
In order to realize the transformational research and application of the "radar + GPS" Umh-NK-01V technology project, Malaysia Pandora Bio Technology aims at the global cutting-edge technology, focusing on integration and investment in new medical projects. In the past year, it has been closely cooperating with Shenzhen KK Medical Research Institute on the research and development and transformation application of new crown infection sequelae diagnosis and treatment technology. In mid-February this year, a new bioengineering technology transformation institute was established in Malaysia, aiming to improve biological Cooperation and exchange of engineering technology professionals, basic research, and biomedicine. It is reported that the work of the hospital has been carried out in an orderly manner according to the plan, and it is starting to prioritize the clinical application research and industrialization implementation of a series of immune-related technologies to alleviate the sequelae of new crown infection, individualized targeted lysis of cancer cells, and activation of the human body’s anti-cancer ability.
Shenzhen, China.
Kuala Lumpur, Malaysia.
It is reported that is a well-known Malaysian Tan Sri who named DR. Yuhao has begun to deploy his biotech companies listed on the OTC section of the United States. By using his strong financial strength and resources, and integrating with his own technological advantages, he will fight against the new crown and epidemic. Cancer and other fields, jointly develop related technologies, and conduct business talks based on clinical research projects. Once the merger is successful in the business talks, it will become the first Asian marketed immune cell therapy with personalized and spot-type immune cell therapy. The realization of this achievement will undoubtedly bring good news for the application of self-developed immune cell technology to Asians, changing the situation of relying only on European and American domination in the past. At the same time, with the deepening and development of cooperation between the two parties, the research and development of biotechnology will also usher in a new chapter.
Comentarios